Therapeutic effects of isoquercetin on ovariectomy-induced osteoporosis in mice.
Adipogenic induction
Bone marrow mesenchymal stem cells
Isoquercetin
Osteogenic induction
Osteoporosis
Journal
Natural products and bioprospecting
ISSN: 2192-2195
Titre abrégé: Nat Prod Bioprospect
Pays: Germany
ID NLM: 101577734
Informations de publication
Date de publication:
08 Jun 2023
08 Jun 2023
Historique:
received:
11
04
2023
accepted:
25
05
2023
medline:
8
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
epublish
Résumé
Bone marrow mesenchymal stem cells (BMSCs) are non-hematopoietic multipotent stem cells capable of differentiating into mature cells. Isoquercetin, an extract from natural sources, has shown promise as a potential treatment for osteoporosis. To investigate the therapeutic effects of isoquercetin on osteoporosis, bone marrow mesenchymal stem cells (BMSCs) were cultured in vitro, and osteogenesis or adipogenesis was induced in the presence of isoquercetin for 14 days. We evaluated cell viability, osteogenic and adipogenic differentiation, as well as mRNA expression levels of Runx2, Alpl, and OCN in osteoblasts, and mRNA expression levels of Pparγ, Fabp4, and Cebpα in adipocytes. The results showed that isoquercetin dose-dependently increased cell viability and promoted osteogenic differentiation, as evidenced by Alizarin Red and alkaline phosphatase staining and mRNA expression levels of Runx2, Alpl, and OCN in osteoblasts (P < 0.05). In contrast, isoquercetin inhibited adipogenic differentiation and decreased the mRNA expression levels of Pparγ, Fabp4, and Cebpα in adipocytes (P < 0.05). In vivo, isoquercetin treatment increased bone quantity and density in an osteoporosis model mice group, as determined by μCT scanning and immunohistochemistry (P < 0.05). These findings suggest that isoquercetin may have therapeutic potential for osteoporosis by promoting the proliferation and differentiation of BMSCs towards osteoblasts while inhibiting adipogenic differentiation.
Identifiants
pubmed: 37289308
doi: 10.1007/s13659-023-00383-2
pii: 10.1007/s13659-023-00383-2
pmc: PMC10250279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Subventions
Organisme : National Natural Science Foundation of China
ID : 22276221
Organisme : National Natural Science Foundation of China
ID : 21675176
Organisme : Fundamental Research Funds for the Central Universities, and South-Central Minzu University
ID : CZP21002
Informations de copyright
© 2023. The Author(s).
Références
Osteoporos Int. 2010 Oct;21(10):1741-50
pubmed: 19949772
J Bone Miner Res. 2009 Feb;24(2):274-82
pubmed: 18847330
Curr Stem Cell Res Ther. 2008 May;3(2):131-45
pubmed: 18473879
Nat Rev Rheumatol. 2015 Aug;11(8):462-74
pubmed: 25900210
Ann N Y Acad Sci. 2011 Feb;1218:15-32
pubmed: 20946579
Crit Rev Food Sci Nutr. 2023;63(1):125-144
pubmed: 34251926
Maturitas. 2011 May;69(1):81-5
pubmed: 21420262
Semin Cell Dev Biol. 2017 Jan;61:12-21
pubmed: 27521519
Int J Mol Sci. 2021 Jan 10;22(2):
pubmed: 33435159
J Bone Miner Res. 2005 Jul;20(7):1085-92
pubmed: 15940361
Bone. 2020 Aug;137:115411
pubmed: 32437874
J Cell Biochem. 2019 Jul;120(7):11842-11852
pubmed: 30746760
Mol Cell Endocrinol. 2009 Apr 10;302(1):86-91
pubmed: 19356626
Front Pharmacol. 2022 Mar 02;13:830205
pubmed: 35308240
Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062
pubmed: 30650219
Eur J Pharmacol. 2019 Dec 15;865:172785
pubmed: 31712059
Indian J Ophthalmol. 2020 Sep;68(9):2002-2003
pubmed: 32823458
Eur J Rheumatol. 2017 Mar;4(1):46-56
pubmed: 28293453
Biochem Pharmacol. 2014 Jun 1;89(3):413-21
pubmed: 24726443
J Bone Miner Metab. 2009;27(6):673-81
pubmed: 19495926
J Bone Miner Res. 2009 Apr;24(4):578-88
pubmed: 19049336